


AMENDMENTS TO THE CLAIMS:

Claims 1-17, 23-26, 30-52, 55 and 57-63 and 98-107 are pending. Claims 18-22, 27-29, 53, 54, 56 and 64-97 are cancelled herein without prejudice or disclaimer. Claims 1, 2, 4-9, 10, 12, 14, 23-26, 30-38, 40-42, 44-48, 50, 52, 55 and 57-63 are amended. Claims 98-107 are added herein. This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently amended) A compound of the formula:



wherein:

R^1 is selected from among the group of hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{12}$, substituted $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl and $\text{C}_1\text{-C}_8$ heteroalkyl, wherein the ~~alkyl~~, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

R^2 is selected from among the group of hydrogen, F, Cl, Br, I, ~~CH_3~~ , CF_3 , CHF_2 , CH_2F , CF_2Cl , CN, $\text{CF}_2\text{OR}^{12}$, CH_2OR , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, substituted $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkenyl and $\text{C}_2\text{-C}_8$ alkynyl, wherein the ~~alkyl~~, haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

R^3 through R^8 each independently is selected from among the group of hydrogen, F, Cl, Br, I, OR^{12} , $\text{NR}^{12}\text{R}^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_2\text{-C}_8$ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups ~~may be~~ are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may is~~ is optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may is~~ is optionally substituted;

R^9 and R^{10} each independently is selected from among the group of hydrogen, F, Cl, Br, I, CN, OR^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}_m(\text{R}^{12})_{2m}\text{OR}^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{C}(\text{O})\text{R}^{13}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups ~~may be~~ are optionally substituted;

R^{11} is selected from among the group of F, Br, Cl, I, CN, OR^{14} , $\text{NR}^{14}\text{R}^{13}$, and SR^{14} ;

R^{12} and R^{13} each independently is selected from the group of hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted;

R^{14} is selected from among the group of hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ heteroalkyl, aryl, heteroaryl, $\text{C}(\text{O})\text{R}^{15}$, CO_2R^{15} and $\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups ~~may be~~ are optionally substituted;

R^{15} and R^{16} each independently is selected from ~~among the group of~~ hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

W is O or S;

X is $N\{R^{14}\}$;

Y is selected from ~~among the group of~~ O, S, $N\{R^{12}\}$ and $NO\{R^{12}\}$;

Z is $N\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound according to claim 1, wherein R^2 is selected from ~~among the group of hydrogen,~~ F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the ~~alkyl,~~ haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

3. (Original) A compound according to claim 1, wherein R^2 is selected from ~~among the group of~~ CF_2OR^{12} , CH_2OR^{12} , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} and $NR^{12}R^{13}$.

4. (Currently amended) A compound according to claim 1, wherein R^2 is selected from ~~among the group of hydrogen,~~ F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 heteroalkyl, C_2 - C_4 alkenyl and C_2 - C_4 alkynyl, wherein the ~~alkyl,~~ haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted.

5. (Currently amended) A compound according to claim 4, wherein R^2 is selected from ~~among the group of hydrogen,~~ F, Cl, CF_3 , CF_2Cl , CF_2H , CFH_2 and ~~optionally~~ substituted C_1 - C_4 alkyl.

6. (Currently amended) A compound according to claim 1, wherein R^9 and R^{10} each independently is selected from among hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted

7. (Currently amended) A compound according to claim 6, wherein R^9 and R^{10} each independently is selected from ~~among the group of~~ hydrogen, F, Cl, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

8. (Currently amended) A compound according to claim 7, wherein R^9 and R^{10} each independently is selected from ~~among the group of~~ hydrogen, F and CH_3 .

9. (Currently amended) A compound according to claim 1, wherein R¹ is selected from ~~among the group of~~ hydrogen, F, Cl, Br, I, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

10. (Currently amended) A compound according to claim 9, wherein R¹¹ is selected from ~~among the group of~~ hydrogen, F, Cl, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

11. (Original) A compound according to claim 9, wherein R¹ is hydrogen or F.

12. (Currently amended) A compound according to claim 1, wherein Y ~~and W each independently~~ is O or S.

13. (Original) A compound according to claim 12, wherein Y ~~and W are each~~ is O.

14. (Currently amended) A compound according to claim 1, wherein R¹¹ is selected from ~~among the group of~~ F, ~~Br~~, Cl, CN, OR¹⁴, NR¹⁴R¹³ and SR¹⁴.

15. (Currently amended) A compound according to claim 14, wherein R¹¹ is selected from ~~among the group of~~ F, Cl, OR¹⁴, SR¹⁴ and NR¹⁴R¹³.

16. (Currently amended) A compound according to claim 15, wherein R¹¹ is selected from ~~among the group of~~ F, Cl, OR¹⁴ and SR¹⁴.

17. (Original) A compound according to claim 16, wherein R¹¹ is OR¹⁴.

18-22. (Cancelled)

23. (Currently amended) A compound according to claim 1, wherein R¹² is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted.

24. (Currently amended) A compound according to claim 23, wherein R¹² is selected from ~~among the group of~~ hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

25. (Currently amended) A compound according to claim 1, wherein R¹³ is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted.

26. (Currently amended) A compound according to claim 25, wherein R¹³ is selected from ~~among the group of~~ hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

27-29. (Cancelled)

30. (Currently amended) A compound according to claim 1, wherein:

R³ and R⁴ each independently is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; or

R³ and R⁵ taken together form a bond; or

R⁴ and R⁶ taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ are optionally substituted.

31. (Currently amended) A compound according to claim 30, wherein R³ and R⁴ each independently is selected from ~~among the group of~~ hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

32. (Currently amended) A compound according to claim 1, wherein:

R⁵ and R⁷ each independently is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R⁵ and R⁷ taken together form a bond.

33. (Currently amended) A compound according to claim 32, wherein R⁵ and R⁷ each independently is selected from ~~among the group of~~ hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl and C₁-C₄ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

34. (Currently amended) A compound according to claim 1, wherein:

R⁶ and R⁸ each independently is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted; or

R⁶ and R⁸ taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted.

35. (Currently amended) A compound according to claim 34, wherein:

R^6 and R^8 each independently is selected from among the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 heteroalkyl, heteroaryl and aryl, wherein alkyl, haloalkyl, heteroaryl and aryl ~~may be~~ are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted.

36. (Currently amended) A compound according to claim 1, wherein:

R^1 is selected from among the group of hydrogen, F, Cl, Br, I, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

R^2 is selected from among the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_6 alkyl; C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the ~~alkyl,~~ haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; and

R^3 and R^4 each independently is selected from among the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

37. (Currently amended) A compound according to claim 36, wherein:

R^5 through R^8 each independently is selected from among the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ are optionally substituted.

38. (Currently amended) A compound according to claim 37, wherein:

R^9 and R^{10} each independently is selected from among the group of hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

R^{12} is selected from among the group of hydrogen, C_1 - C_6 alkyl C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted; and

R¹⁴ is selected from ~~among the group of~~ hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C(O)R¹⁵, CO₂R¹⁵ and C(O)NR¹⁵R¹⁶, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

39. (Previously presented) A compound according to claim 38, wherein Y is O or S.

40. (Currently amended) A compound according to claim 1, wherein said compound is selected from ~~among the group of~~:

- 6-Methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-Isopropyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-Allyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- 4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrole-[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-6,6a,7,8,9,9a(*cis*)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano[*i*]pyrrole-[2,3-*g*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-6,6a,7,8,9,9a(*cis*)-Hexahydro-6-ethyl-4-trifluoromethylcyclopentano-[*i*]pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;
- (±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-furanylmethyl)-4 trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
- (±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoro-ethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,8,9,9a(*cis*),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethylcycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-(2-ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

~~6-Ethyl-5-methyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

~~(±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

~~6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

9-Trifluoroethyl-4-trifluoromethyl-9*H*-benzo[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[*i*]pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(2-Ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6*H*-pyrrolo-[2,3-*g*]quinolin-2(1*H*)-one;

5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinoline;

6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

(+)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7-Allyl-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

6-Ethyl-7-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

(+)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(-)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7,8-Dihydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

6-(2,2,2-Trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

8-Chloro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and
5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

41. (Previously presented) A compound according to claim 1, wherein said compound is selected from the group consisting of:

(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;
(±)-6,6*a*,7,8,9,9*a*(*cis*)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano[*i*]pyrrolo-[2,3-*g*]quinolin-2(1*H*)-one;
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethyl-cyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-4*c*,5,6,7,8,8*a*(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(35)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;

6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[*i*]pyrrolo[2,3-*g*]-quinolin-2(1*H*)-one;


7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;


6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(+)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and

(-)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

42. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:





wherein:

R^1 is selected from ~~among the group~~ of hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}R^{13}$, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl and C_1 - C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

R^2 is selected from ~~among the group of hydrogen~~, F, Cl, Br, I, CH_3 , CF_3 , CHF_2 , CH_2F , CF_2Cl , CN, CF_2OR^{12} , CH_2OR^{12} , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}R^{13}$, substituted C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, C_2 - C_8 alkenyl and C_2 - C_8 alkynyl, wherein the ~~alkyl~~, haloalkyl, heteroalkyl, alkenyl and alkynyl groups ~~may be~~ are optionally substituted;

R^3 through R^8 each independently is selected from ~~among the group of~~ hydrogen, F, Cl, Br, I, OR^{12} , $NR^{12}R^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, C_2 - C_8 alkynyl, C_2 - C_8 alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups ~~may be~~ are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted;

R^9 and R^{10} each independently is selected from ~~among the group of~~ hydrogen, F, Cl, Br, I, CN, OR^{12} , $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}C(O)R^{13}$, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups ~~may be~~ are optionally substituted;

R^{11} is selected from ~~among the group of~~ hydrogen, F, Br, Cl, I, CN, OR^{14} , $NR^{14}R^{13}$ and SR^{14} ;

R^{12} and R^{13} each independently is selected from ~~among the group of~~ hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted;

R^{14} is selected from ~~among the group of~~ hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups ~~may be~~ are optionally substituted;

R^{15} and R^{16} each independently is selected from ~~among the group of~~ hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;

W is O or S;

X is $N\{R^{14}\}$;

Y is selected from ~~among the group of~~ O, S, $N\{R^{12}\}$ and $N\{OR^{12}\}$;

Z is $N\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

43. (Original) A pharmaceutical composition according to claim 42, wherein the carrier is suitable for enteral, parenteral, suppository, or topical administration.

44. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^1 is selected from ~~among the group of~~ hydrogen, F, Cl, Br, I, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

45. (Currently amended) A pharmaceutical composition according to claim 44, wherein R^1 is selected from among the group of hydrogen, F, Cl, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

46. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^2 is selected from among the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the ~~alkyl~~, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

47. (Currently amended) A pharmaceutical composition according to claim 46, wherein R^2 is selected from among the group of hydrogen, F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 heteroalkyl, wherein the ~~alkyl~~, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

48. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^9 and R^{10} each independently is selected from among the group of hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

49. (Currently amended) A pharmaceutical composition according to claim 48, wherein R^9 and R^{10} each independently is selected from among the group of hydrogen, F and CH_3 .

50. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^{11} is selected from among the group of F, ~~Br~~, Cl, CN, OR^{14} , $NR^{14}R^{13}$ and SR^{14} .

51. (Currently amended) A pharmaceutical composition according to claim 50, wherein R^{11} is selected from among the group of F, Cl, OR^{14} , SR and $NR^{14}R^{13}$.

52. (Currently amended) A pharmaceutical composition according to claim 42, wherein Y ~~and W each independently~~ is O or S.

53. (Cancelled)

54. (Cancelled)

55. (Currently amended) A pharmaceutical composition according to claim 42, wherein R^{12} is selected from among the group of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted.

56. (Cancelled)

57. (Currently amended) A pharmaceutical composition according to claim 42, wherein:
R³ and R⁴ each independently is selected from among the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; or
R³ and R⁵ taken together form a bond; or
R⁴ and R⁶ taken together form a four to six membered carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted.
58. (Currently amended) A pharmaceutical composition according to claim 42, wherein:
R⁵ and R⁷ each independently is selected from among the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; or
R⁵ and R⁷ taken together form a bond.
59. (Currently amended) A pharmaceutical composition according to claim 42, wherein:
R⁶ and R⁸ each independently is selected from among the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted; or
R⁶ and R⁸ taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted.
60. (Currently amended) A pharmaceutical composition according to claim 42, wherein:
R¹ is selected from among the group of hydrogen, F, Cl, Br, I, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;
R² is selected from among the group of hydrogen, F, Cl, Br, CF₃, CF₂Cl, CF₂H, CFH₂, substituted C₁-C₆ alkyl; C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the ~~alkyl~~, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; and
[[R3]] R³ and [[R4]] R⁴ each independently is selected from among the group of hydrogen, C₁-C₆ alkyl, ~~C1-C6~~ C₁-C₆ haloalkyl and ~~C1-C6~~ C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.
61. (Currently amended) A pharmaceutical composition according to claim 60, wherein:
R⁵ through R⁸ each independently is selected from among the group of hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~ is optionally substituted.

62. (Currently amended) A pharmaceutical composition according to claim 61, wherein: R^9 and R^{10} each independently is selected from ~~among the group of~~ hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted;


R^{12} is selected from ~~among the group of~~ hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~ are optionally substituted; and


R^{14} is selected from ~~among the group of~~ hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~ are optionally substituted.

63. (Currently amended) A pharmaceutical composition according to claim 62, wherein Y is O or S.

64-97. (Cancelled)

98. (New) A compound of formula:





wherein:

R¹ is selected from among hydrogen, F, Cl, Br, I, NO₂, OR¹², SR¹², SOR¹², SO₂R¹², NR¹²R¹², C₁-C₈ alkyl, C₁-C₈ haloalkyl and C₁-C₈ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R² is selected from among F, Cl, Br, I, CF₃, CHF₂, CH₂F, CF₂Cl, CN, CF₂OR¹², CH₂OR, OR¹², SR¹², SOR¹², SO₂R¹², NR¹²R¹³, alkyl selected from among ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, *tert*-amyl, pentyl, hexyl, heptyl, octyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkenyl and C₂-C₈ alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

R³ through R⁸ each independently is selected from among hydrogen, F, Cl, Br, I, OR¹², NR¹²R¹³, SR¹², SOR¹², SO₂R¹², C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkynyl, C₂-C₈ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or

R³ and R⁵ taken together form a bond; or

R⁵ and R⁷ taken together form a bond; or

R⁴ and R⁶ taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring is optionally substituted; or

R⁶ and R⁸ taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring is optionally substituted;

R^9 and R^{10} each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR^{12} , $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}C(O)R^{13}$, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R^{11} is selected from among F, Br, Cl, I, CN, OR^{14} , $NR^{14}R^{13}$, and SR^{14} ;

R^{12} and R^{13} each independently is selected from among hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

R^{14} is selected from among hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R^{15} and R^{16} each independently is selected from among hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is $N\{R^{14}\}$;

Y is selected from the group of O, S, $N\{R^{12}\}$ and $NO\{R^{12}\}$;

Z is $N\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

99. (New) A compound according to claim 98, wherein the carrier is suitable for enteral, parenteral, suppository, or topical administration.

100. (New) A compound according to claim 98, wherein R^1 is selected from among hydrogen, F, Cl, Br, I, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.

101. (New) A compound according to claim 98, wherein R^9 and R^{10} each independently is selected from among hydrogen, F, Cl, Br, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.

102. (New) A compound according to claim 98, wherein R^{11} is selected from among F, Cl, CN, OR^{14} , $NR^{14}R^{13}$ and SR^{14} .

103. (New) A compound according to claim 98, wherein Y is O or S.

104. (New) A compound according to claim 98, wherein R¹² is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted.

105. (New) A compound according to claim 98, wherein:

R³ and R⁴ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R³ and R⁵ taken together form a bond; or

R⁴ and R⁶ taken together form a four to six membered carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring is optionally substituted.

106. (New) A compound according to claim 42, wherein:

R⁵ and R⁷ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R⁵ and R⁷ taken together form a bond.

107. (New) A compound according to claim 42, wherein:

R⁶ and R⁸ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

R⁶ and R⁸ taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring is optionally substituted.